SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Financials Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Equities
6990
CNE1000062J1
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 175.9 HKD | +0.92% |
|
+3.05% | +70.94% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 20,501 | 36,336 | - | - |
| Enterprise Value (EV) 2 | 19,042 | 35,761 | 35,562 | 35,361 |
| P/E ratio | -33.4 x | -61.5 x | -55.8 x | -383 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 13.3 x | 31.7 x | 24.1 x | 14.5 x |
| EV / Revenue | 12.4 x | 31.2 x | 23.6 x | 14.1 x |
| EV / EBITDA | -57.9 x | -64.5 x | -65.8 x | 147 x |
| EV / FCF | -839 x | -43.7 x | -83.4 x | -329 x |
| FCF Yield | -0.12% | -2.29% | -1.2% | -0.3% |
| Price to Book | - | 19.7 x | 30.2 x | 16.8 x |
| Nbr of stocks (in thousands) | 219,195 | 222,844 | - | - |
| Reference price 3 | 102.9 | 175.9 | 175.9 | 175.9 |
| Announcement Date | 3/25/24 | - | - | - |
1HKD in Million2CNY in Million3HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 1,540 | 1,145 | 1,507 | 2,501 |
| EBITDA 1 | - | -328.6 | -554.4 | -540.1 | 240.5 |
| EBIT 1 | - | -383.4 | -679.9 | -750.2 | -296.2 |
| Operating Margin | - | -24.89% | -59.36% | -49.8% | -11.84% |
| Earnings before Tax (EBT) 1 | - | -467.7 | -584.6 | -605.6 | -35.38 |
| Net income 1 | -616.1 | -574.1 | -550.3 | -609.8 | -72.98 |
| Net margin | - | -37.27% | -48.05% | -40.47% | -2.92% |
| EPS 2 | -6.201 | -3.080 | -2.858 | -3.151 | -0.4599 |
| Free Cash Flow 1 | - | -22.69 | -819 | -426.2 | -107.3 |
| FCF margin | - | -1.47% | -71.5% | -28.29% | -4.29% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 6/28/23 | 3/25/24 | - | - | - |
1CNY in Million2HKD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|
| Net sales 1 | 1,046 | 494.3 | 854.8 | 663 |
| EBITDA | - | - | - | - |
| EBIT 1 | 95.89 | - | -179 | -642.3 |
| Operating Margin | 9.17% | - | -20.94% | -96.88% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | - | - | - |
| Net margin | - | - | - | - |
| EPS 2 | -0.1829 | -2.896 | -1.170 | -3.270 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 8/28/23 | 3/25/24 | - | - |
1CNY in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 1,459 | 575 | 774 | 975 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -22.7 | -819 | -426 | -107 |
| ROE (net income / shareholders' equity) | - | - | -29.2% | -67.9% | -7.97% |
| ROA (Net income/ Total Assets) | - | -25.5% | -23.2% | -26% | 7.2% |
| Assets 1 | - | 2,251 | 2,368 | 2,341 | -1,014 |
| Book Value Per Share 2 | - | - | 8.940 | 5.820 | 10.50 |
| Cash Flow per Share 2 | - | 0.3500 | -2.900 | -0.2400 | 4.910 |
| Capex 1 | - | 82.3 | 158 | 148 | 147 |
| Capex / Sales | - | 5.34% | 13.8% | 9.8% | 5.88% |
| Announcement Date | 6/28/23 | 3/25/24 | - | - | - |
1CNY in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
175.9
HKD
Average target price
191.6
HKD
Spread / Average Target
+8.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +70.94% | 5.02B | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- 6990 Stock
- Financials Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
